Kairos Pharma’s (KAPA) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $9.00 target price on the stock.

Kairos Pharma Trading Down 2.9 %

Shares of KAPA opened at $1.33 on Tuesday. Kairos Pharma has a twelve month low of $0.85 and a twelve month high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.